I suspect their free cashflow from existing operations is decreasing and uncertainty regarding a potential price war with telstra,optus and others will take it a few years to achieve a turnaround. High risk poker imo.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%